Phase 2 Lung Cancer Trial, Not Yet Recruiting NCT07177092 Sponsor: Jianxing He Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Not Yet Recruiting

NCT07177092
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 to 75 years, of any sex.
  • People with a confirmed diagnosis of stage III or IV non-squamous non-small cell lung cancer (a specific type of lung cancer) that cannot be surgically removed, as determined by a specialist team.
  • People whose lung cancer has a specific genetic change — either an "exon 19 deletion" or an "L858R mutation" — in a gene called EGFR, confirmed by an approved test.
  • People who have not previously received any systemic treatment (such as chemotherapy or targeted therapy) for their lung cancer.
  • People with a good general level of physical functioning, rated 0 or 1 on a standard medical scale (meaning largely active and able to carry out daily activities with little or no restriction).
  • People with an estimated life expectancy of at least 6 months.
  • People whose primary lung tumour measures at least 1 cm, and who have at least one measurable area of disease remaining after any surgery, as assessed using standard imaging criteria.
  • People with adequate blood cell counts — specifically, a sufficient level of infection-fighting cells, platelets, and red blood cells, as measured by blood tests.
  • People with adequate liver function, based on blood test results within accepted ranges (with slightly different allowances if liver metastases are present).
  • People with adequate kidney function, based on blood test results within accepted ranges.
  • People with adequate lung function, meeting at least one of the following: a breathing test result (FEV1) of at least 1.2 litres or at least 40% of the expected value; a specific ratio of breathing measurements (FEV1/FVC) of at least 0.7; or a lung gas transfer test result of at least 40% of the expected value. If breathing test results fall below certain thresholds, additional exercise-based tests may be recommended to assess lung reserve (confirm with trial site).
  • People who have been assessed by the study team and considered suitable for surgery to remove the primary tumour.
  • People who have provided written consent to participate and are willing to follow the study requirements.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose lung cancer has other known EGFR genetic changes beyond the specific ones required for this trial.
  • People whose lung cancer tissue shows signs of a mixed type involving small-cell lung cancer, or who have a history of their cancer changing into small-cell lung cancer.
  • People with a history of a primary immune system disorder, or who have previously received a transplant of an organ or bone marrow from another person.
  • People with active, currently spreading cancer in the brain. People with previously treated brain metastases may still be considered if their condition has been neurologically stable for at least 2 weeks before joining, and they are either not taking steroid medications or are on a stable or reducing low dose (confirm with trial site).
  • People who are pregnant.
  • People with a serious ongoing health condition — including uncontrolled systemic illness, psychiatric illness, active or uncontrolled infection, or significant abnormal test results — that the study team believes could interfere with participation or the interpretation of results.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026

Contact this trial

Phone: 86+020-83062807

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Jianxing He
Registry
ClinicalTrials.gov
Start date
8 September 2025
Est. completion
1 October 2028

Primary endpoints

Progression-free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov